Therapy of sustained ventricular arrhythmias with amiodarone: Prediction of efficacy with serial electrophysiologic studies

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 1, Issue 2, 1996, Pages 123-132

  Nasir Jr , Nadim ^a   Swarna, Udaya S ^a   Boahene, Kwabena A ^a   Doyle, Timothy K ^a   Pacifico, Antonio ^a  

^a Texas Arrhythmia Institute   (United States)

Author keywords

Amiodarone; Predictive value; Programmed electrical stimulation

Indexed keywords

EID: 0000887792     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/107424849600100206     Document Type: Article

References (27)

1. Myers M, Peter T, Weiss D,et al.Benefit and risks of longterm amiodarone therapy for sustained ventricular tachycardia/fibrillation: Minimum of three-year follow-up in 145 patients. Am Heart J 119:8, 1990.
2. Heger JJ, Prystowsky EN, Jackman WM,et al.Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305:539, 1990.
3. Kaski JC, Girotti LA, Messuti H, Rutitzky B, Rosenbaum MB. Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation 64:273, 1981.
4. Weinberg BA, Miles WM, Klein LS,et al.Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 125:109, 1993.
5. Greenberg ML, Lerman BB, Shipe JR, Kaiser DL, DiMarco JP. Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. J Am Coll Cardiol 9:1148, 1978.
6. Fogoros RN, Anderson KP, Winkle RA, Swerdlow DC, Mason JW. Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 68:88, 1983.
7. Hamer AW, Finerman WB, Peter T, Manderl WJ. Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tach-yarrhythmias. Am Heart J 102:992, 1981.
8. Nademanee K, Hendrickson J, Singh BN. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: Potent suppression of spontaneously occurring tach-yarrhythmias versus inconsistent abolition of induced ventricular tachycardia. Am Heart J 103:950 1982.
9. Veltri EP, Reid PRR, Platia EV. Griffith LSC. Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia. Am J Cardiol 55:375, 1985.
10. Nasir N Jr, Doyle TK, Wheeler SH, Pacifico A. Usefulness of Holter monitoring in predicting efficacy of amiodarone therapy for sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol 73:554, 1994.
11. McGovern BM, Garan H, Malacoff RF,et al.Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. Am J Cardiol 53:1558, 1984.
12. Horowitz LN, Greenspan AM, Spielman SR,et al.Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 55:367, 1985.
13. Zhu J, Haines DE. Lerman BB, DiMarco JP. Predictors of efficacy of amiodarone and characteristics of recurrence of arrhythmia in patients with sustained ventricular tachycardia and coronary artery disease. Circulation 76:802, 1987.
14. Greenspon AJ, Volosin KJ, Greenberg RM, Jefferies L, Rotmensch HH. Amiodarone therapy: Role of early and late electrophysiologic studies. J Am Coll Cardiol 11:117, 1988.
15. Mitchell LB, Wyse G, Gillis AM, Duff HJ. Electropharmacology of amiodarone therapy initiation. Circulation 80:34, 1989.
16. Kadish AH, Marchilinski FE, Josephson ME, Buxton AE. Amiodarone: Correlation of early and late electrophysiologic studies with outcome. Am Heart J 112:1134, 1986.
17. Cooper MJ, Hunt LJ, Palmer KJ,et al.Quantitation of day to day variability in mode of induction of ventricular tachyarrhythmias by programmed stimulation. J Am Coll Cardiol 11:101, 1988.
18. Cooper MJ, Koo CC, Skinner MP,et al.Comparison of immediate versus day to day variability of ventricular tachycardia induction by programmed stimulation. J Am Coll Cardiol 13:1599, 1989.
19. McPherson CA, Rosenfeld LE. Batsford WP. Day-to-day reproducibility of responses to right ventricular programmed electrical stimulation: Implications for serial drug testing. Am J Cardiol 55:689, 1985.
20. Shannon JA, Hammill SC, Gersh BU. Predictive value of early electrophysiologic testing in determining long-term outcome with amiodarone treatment in patients with sustained ventricular tachycardia. Mayo Clinic Proc 66:1114, 1991.
21. Kus T, Dubuc M, Lambert C, Shenasa M. Efficacy of propafenone in preventing ventricular tachycardia: Inverse correlation with rate-related prolongation of conduction time. J Am Coll Cardiol 16:1229, 1990.
22. Tuna IC, Qi A, Gornick C, Bolman RM, Benditt DG. Kinetics of electrophysiologic changes during oral loading of amiodarone and after withdrawal of amiodarone in the unsedated dog. Circulation 72:1380, 1985.
23. Talajic M, DeRoode MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: Evidence for clinically relevant activity of the metabolite. Circulation 75:265, 1987.
24. Nattel S, Davies M, Quantz M. The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. Circulation 77:200, 1988.
25. Waller TJ, Kay HR, Speilman SR, Kutalke SP, Greenspon AM, Horowitz LN. Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: Criteria of efficacy in patients with sustained ventricular tachyarrhythmia. J Am Coll Cardiol 10:83, 1987.
26. Marchlinski FE, Buxton AE, Miller JM, Vassalo JA, Flores BT. Josephson ME. Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia. Circulation 74:1037, 1986.
27. Klein LS, Fineberg N, Heger JJ,et al.Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study. Am J Cardiol 61:1024, 1988.